The Claim

Rapamycin use is associated with an increased risk of serious infections, such as pneumonia, in older adults, even when administered at low and intermittent doses, due to its immunosuppressive properties.

Source: We Spent $724,637 Testing Rapamycin. What We Found Shocked Us.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
73score
Challenges
64score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
3 studies reviewed
In plain English

Taking rapamycin, even in small doses now and then, might increase the chance of getting serious infections like pneumonia in older people because it can weaken the immune system.

See the scientific wording

Rapamycin use is associated with an increased risk of serious infections, including pneumonia, due to its immunosuppressive properties, even at low intermittent doses in older adults.

What the research says

3 studies

  1. Study: Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA‐EX‐01 Randomised, Double‐Blind, Placebo‐Controlled Trial

    The study gave older adults a weekly dose of rapamycin and found one case of pneumonia that might be linked to the drug, which supports the idea that even low doses could increase infection risk.

Related videos

We Spent $724,637 Testing Rapamycin. What We Found Shocked Us.

Dr Brad Stanfield

We Spent $724,637 Testing Rapamycin. What We Found Shocked Us.

Read analysis

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.